Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

69.48 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59
Open 69.48
Bid (Size) 68.71 (1)
Ask (Size) 70.29 (1)
Prev. Close 69.48
Today's Range 69.48 - 69.48
52wk Range 67.75 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga

Performance

YTD
-29.14%
-29.14%
1 Month
-22.78%
-22.78%
3 Month
-18.23%
-18.23%
6 Month
-20.81%
-20.81%
1 Year
-20.17%
-20.17%

More News

Read More
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Via Investor's Business Daily
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
Via Talk Markets
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
Via Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
Via Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Via Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Via Benzinga
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.